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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 












a cohort study 
The Lancet | 
Article 
• Cohort study of long-
term health 
consequences of 1733 
adult patients with 
COVID-19 who have 
been discharged from a 
hospital in Wuhan, China 
between 7 Jan 2020 and 
29 May 2020 (2469 in 
total discharged but 736 
were excluded from this 
study) 
• At 6 months after acute 
infection, COVID-19 
survivors mainly suffered 
fatigue or muscle 
weakness, sleep 
difficulties, and anxiety 
or depression 
• Patients that were more 
severely ill during 
hospitalisation had more 
severe impaired 
pulmonary diffusion 
capacities and abnormal 
chest imaging 
manifestations 
• Authors raise concern 




















• To-date, 750,000 
patients with COVID-19 
worldwide have required 
mechanical ventilation 
and thus are at high risk 
of acute brain 
dysfunction (coma and 
delirium) 
• Multicentre cohort study 
of 2088 patients from 69 
adult intensive care units 
across 14 countries. 
Median age 64 years 
(IQR 54 to 71) 
• Acute brain dysfunction 
was highly prevalent and 
prolonged in critically ill 
patients with COVID-19 
• This study shows that 
clinicians have reverted 
to outdated and 
potentially harmful 
treatment strategies of 
deep sedation with 
widespread use of 
benzodiazepine 
infusions, immobilisation, 
and isolation from 
families because of the 
COVID-19 pandemic 
• This study provides 
evidence that clinicians 
should aim to use 
supportive and proven 
therapies that avoid 
deep sedation with 
benzodiazepine 
infusions, and facilitate 
safe in-person or virtual 


















• Recent information 
suggest that around 26% 
of people with COVID-19 
globally have been 
admitted to an intensive 
care unit (ICU), and of 
these people, almost 
one-third have died 
• Care bundles are a set 
of ‘evidence-based’ 







carried out together 
when delivering care to 
patients with the same 
condition or in the same 
healthcare setting 
• WHO commissioned this 
‘scoping’ review to 
identify how much and 
what type of evidence is 
available on the use of 
care bundles for patients 
in the ICU setting 
suffering from COVID-
19, acute respiratory 
distress syndrome 
(ARDS) or viral 
pneumonia 
• Research specific to 
patients with COVID-19 
that compares patients 
receiving care bundles 
and not receiving care 
bundles is limited. 
Information is also 
needed on how care 
bundles can best be 
implemented in practice, 
and difficulties that may 
be associated with this 






Jan 2021 Superspreading 
event of SARS-
CoV-2 infection 




















specific settings in 
which 
superspreading 





control measures  
• Note: for SARS-
CoV-2, an R0 of 2-







• Authors highlight 
that crowds in 
enclosed indoor 
settings with poor 
ventilation maybe 
considered at high 
risk for 
transmission 



















data etc.) of VOC 
202012/01 having a 
transmission 
advantage 
• Note estimates of 
transmission 
advantage given 
apply to a period 
where high levels of 
social distancing 


















• Using a 
combination of daily 
local SARS-CoV-2 
incidence data and 
weekly genomic 
surveillance data, 
authors find strong 
and consistent data 
that B.1.1.7 
proliferated (R>1) 
















Letter to the 
Editor 
• In a retrospective 
cohort study of 
11,000 UK 
healthcare workers 










• This apparent 
immunity to re-
infection was 
maintained for at 
least 6 months 
• Further studies 




























• Example of where 









• On 18 March 2020, 
a total of 3 distinct 
clusters of COVID-
19 cases were 
identified at Bach 
Mai Hospital (BMH) 





• Diagnosis of the 
initial 3 COVID-19 
cases led to contact 
tracing, symptom 
screening and 
testing of 495 
persons and limited 
quarantine of 
affected institutes or 
departments 
• When 27 staff 
members in the 
catering company 
tested positive for 
SARS-CoV-2, the 
entire BMH staff 
(7,664) was put 
under quarantine 
• Contact tracing in 
the community 




• After 3 weeks, the 
hospital outbreak 
was contained with 




















• This study evaluated 
tocilizumab and sarilumab 




• Adult patients with Covid-
19, within 24h of 
commencing organ 
support in an intensive 
care unit, were 
randomised to receive 
either tocilizumab or 
sarilumab or standard 
care (control) 
• In critically ill patients with 
COVID-19 receiving 










survival (reduced the 









NEJM | Article 
• Convalescent plasma 
administered to 
hospitalised patients has 
been shown to be 
unsuccessful – possibly 
because antibodies need 
to be administered earlier 
in the infection 
• Randomised, double-
blind, placebo-controlled 
trial of convalescent 
plasma with high IgG 
titers against SARS-CoV-
2 in older adult patients 
within 72 hours after the 
onset of mild COVID-19 
symptoms 
• Primary endpoint: severe 
respiratory disease 
• Note trial was stopped 
early at 76% of projected 
sample size due to 
considerable decline in 
numbers of COVID-19 
cases challenging trial 
enrolment 
• 160 patients randomised 
• Early administration of 
high-titer convalescent 
plasma against SARS-
CoV-2 to mildly ill infected 
older adults reduced risk 
of progression to severe 
disease 
• Larger trials needed to 













NEJM | Article 
• Monoclonal antibody LY-
CoV555 has been 
associated with a 
decrease in viral load and 
the frequency of 
hospitalisations or 
emergency department 







• This platform trial 
assesses the effect of this 
antibody in patients who 
are hospitalised with 
Covid-19 
• Monoclonal antibody LY-
CoV555, when co-
administered with 
remdesivir, did not 
demonstrate efficacy 
among hospitalised 
patients who had Covid-








17.12.2020 T cell and 
antibody 
responses 
induced by a 










• Exploratory analyses of 
the immune responses in 
adults, aged 18-55 year, 
up to 8 weeks after 
vaccination with a single 
dose of ChAdOx1 nCoV-
19 with Th1-induced 




















• Safety and humoral and 
cellular immunogenicity 
of ChAdOx1 nCoV-19 
vaccine in subgroups of 
trial volunteers allocated 
to receive homologus 
full-dose or half-dose 
ChAdOx1 booster 
vaccine 56 days 
following prime 
vaccination 
• A booster dose of 
ChAdOx1 nCoV-19 is 
safe and better tolerated 
than priming doses 
• Two doses of the 
ChAdOx1 nCoV-19 
boost antibody 





in phase ’1/2 trial 
participants 







report of an 
open-label, 





• INO-4800 (a DNA 
vaccine) demonstrated 
excellent safety and 
tolerability and was 
immunogenic in 100% 
(38/38) of vaccinated 
subjects eliciting either 

































• This paper aims to ‘serve as 
a starting point’ for the NTD 
community, and especially 
in LMICs, to work quickly, 
diligently and in close 
collaboration with decision-
makers and stakeholders, 
across sectors at national 
and international level to 
secure its position and 
access much needed 
financial support to sustain 
and revitalise NTD control 















SSHAP | Brief 
• Explains how social 
science can inform 
infodemiology by making it 
more attuned to different 
social, political and 





the relationships between 
people and formal 
institutions which can help 
infodemic managers to 
work with people to make 
decisions based on the 
most accurate and 
appropriate information 
• This brief offers six ways 
to do it 
  
Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
Jan 2021 Tuberculosis and malaria in the age of COVID-
19 
The Lancet Infectious Diseases 
| Editorial 
Jan 2021 Equitable distribution of COVID-19 vaccines The Lancet Infectious 
Diseases | Newsdesk 
09.01.2021 Health systems neglected by COVID-19 
donors 
The Lancet | World Report 
08.01.2021 A New Year’s Wish: Invest in Data CGD | Blog 
08.01.2021 Sedation in mechanically ventilated patients 
with COVID-19 
The Lancet Respiratory 
Medicine | Comment 
05.01.2021 Public health emergency or opportunity to 
profit? The two faces of the COVID-19 
pandemic 
The Lancet Diabetes & 
Endocrinology | Comment 
04.01.2021 G7: Make plans to share excess vaccine now CGD | Blog 
27.12.2020 International Day of Epidemic Preparedness 
(first one!) 
WHO | News 
18.12.2020 Why the evolution of vaccine resistance is less 
of a concern than the evolution of drug 
resistance 
PNAS | Perspective 
15.12.2020 ODA in turmoil: why aid definitions and targets 
will come under pressure in the pandemic age, 
and what might be done about it? 
CGD | Policy paper 
15.12.2020 Playing snakes and ladders with international 
development aid: when fragile accounting 
rules and political pressures mix 
CGD | Blog 
Guidelines, Statements & Tools 
 Publication 
Date 










• Guidance for laboratories on 
maximizing the impact of SARS-
CoV-2 sequencing now and other 
merging pathogens in the future 
   
 
Dashboards & Trackers 









& policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  



















Nigeria CDC  Norwegian 
Institute of 
Public Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 





US NIH   Our World in 
Data: C19 
Testing 






Our World in 
Data  




COVID-evidence        
Global 5050    UK   IFPRI COVID-
19 Policy 
Response Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-
19 Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 

















LSTM Stop TB 
Partnership 








  IDA 











































































Institute of Public 
Health 
    






Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     




 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 





  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
  
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during 
the COVID-19 
pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
is the tole of PFM in 
the “new normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental 
wellbeing of 
community health 
workers on the 
COVID-19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the 




  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
4-week 
discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
Online event 1h30 CGD 
before we approve 
efficacious COVID-19 
vaccines 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 












Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 




WHO Academy and 
WHO Info mobile 
applications 





Modelling and Policy 









11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 












online brief with Dr 
David Nabarro 














training for the 
coronavirus disease 
outbreak 

































6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 





of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
  
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
© Crown copyright 2021. 
